Literature DB >> 17410574

Ofloxacin-delivery system of a polyanhydride and polylactide blend used in the treatment of bone infection.

Liaobin Chen1, Hui Wang, Jun Wang, Man Chen, Liang Shang.   

Abstract

We developed a local drug-release system consisting of two biodegradable polymers, poly(sebacic anhydride) (PSA) and poly-D,L-lactide (PLA), for the treatment of chronic osteomyelitis. PSA and PLA were dissolved and blended at different ratios in tetrahydrofuran. Ofloxacin was loaded with an 8:1 weight ratio of the blend to the drug. The ofloxacin-containing beads of the PSA/PLA blend were made by preheating and compressing them in a mold. The in vitro drug release showed that changing the ratio between the two polymers caused the effective ofloxacin-release duration to vary from 6 to 68 days. The ofloxacin-containing beads with 10% PSA and 90% PLA produced an inhibition zone for the bacteria Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa within 89 days of the experiment. The in vivo drug release of the beads in rabbits demonstrated that the average ofloxacin concentration in the local bone was 20.1 +/- 10.3 microg/g, while that in the plasma was 35.6 +/- 18.8 ng/mL, within 8 weeks. Roentgenography, bacterial cultures, and histological examinations showed that the local release of ofloxacin by the beads could cure osteomyelitis in rabbits. Our findings suggested that using PSA/PLA blends with different ratios as carriers for antibiotics might be useful in the treatment of chronic osteomyelitis and in the prophylaxis of bone infection.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17410574     DOI: 10.1002/jbm.b.30832

Source DB:  PubMed          Journal:  J Biomed Mater Res B Appl Biomater        ISSN: 1552-4973            Impact factor:   3.368


  8 in total

1.  Development of porous HAp and β-TCP scaffolds by starch consolidation with foaming method and drug-chitosan bilayered scaffold based drug delivery system.

Authors:  B Kundu; A Lemos; C Soundrapandian; P S Sen; S Datta; J M F Ferreira; D Basu
Journal:  J Mater Sci Mater Med       Date:  2010-07-20       Impact factor: 3.896

Review 2.  Nanostructured platforms for the sustained and local delivery of antibiotics in the treatment of osteomyelitis.

Authors:  Vuk Uskokovic
Journal:  Crit Rev Ther Drug Carrier Syst       Date:  2015       Impact factor: 4.889

3.  In vitro release kinetics and physical, chemical and mechanical characterization of a POVIAC®/CaCO3/HAP-200 composite.

Authors:  Javier Aragón; Ramón González; Gastón Fuentes; Luca Palin; Gianluca Croce; Davide Viterbo
Journal:  J Mater Sci Mater Med       Date:  2011-12-27       Impact factor: 3.896

Review 4.  Biomaterials approaches to treating implant-associated osteomyelitis.

Authors:  Jason A Inzana; Edward M Schwarz; Stephen L Kates; Hani A Awad
Journal:  Biomaterials       Date:  2015-12-18       Impact factor: 12.479

5.  Insights on the properties of levofloxacin-adsorbed Sr- and Mg-doped calcium phosphate powders.

Authors:  Catarina F Marques; Ana C Matos; Isabel A C Ribeiro; Lídia M Gonçalves; Ana Bettencourt; José M F Ferreira
Journal:  J Mater Sci Mater Med       Date:  2016-06-14       Impact factor: 3.896

Review 6.  Nanotechnology in the Diagnosis and Treatment of Osteomyelitis.

Authors:  Demi Zapata; Jordan Higgs; Hunter Wittholt; Kishore Chittimalli; Amanda E Brooks; Pranothi Mulinti
Journal:  Pharmaceutics       Date:  2022-07-27       Impact factor: 6.525

7.  Polymerizable vancomycin derivatives for bactericidal biomaterial surface modification: structure-function evaluation.

Authors:  McKinley C Lawson; Richard Shoemaker; Kevin B Hoth; Christopher N Bowman; Kristi S Anseth
Journal:  Biomacromolecules       Date:  2009-08-10       Impact factor: 6.988

8.  Experimental study of PLLA/INH slow release implant fabricated by three dimensional printing technique and drug release characteristics in vitro.

Authors:  Gui Wu; Weigang Wu; Qixin Zheng; Jingfeng Li; Jianbo Zhou; Zhilei Hu
Journal:  Biomed Eng Online       Date:  2014-07-19       Impact factor: 2.819

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.